LumiraDx and Chembio announce COVID-19 Strategic Partnership

Tuesday, September 22, 2020

LumiraDx UK Ltd., today announced plans it has entered a strategic partnership with Chembio Diagnostics (Nasdaq: CEMI) to develop point of care test solutions for the detection and monitoring of the COVID-19 virus, and IgG and IgM antibodies. The agreement builds on the strengths of both companies in delivering novel point of care test solutions.

“We are pleased to expand our relationship with Chembio as our partner given the company’s expertise and speed in developing high-quality point-of-care assays. By joining forces and bringing together the best of these two companies, we believe we will become the chosen approach for the detection and monitoring of the COVID-19 virus, which has become a worldwide pandemic,” stated Ron Zwanziger, LumiraDx’s Chairman and Chief Executive Officer.

Point of care test solutions will be developed on both the LumiraDx and Chembio DPP platforms.

The LumiraDx Platform is a simple, easy to use, portable point of care test system. Its microfluidic technology enables accurate test results in line with those from hospital laboratory analyzers, using small patient samples, including capillary fingerstick blood. Fast results are delivered in minutes at the patient side and can be connected directly into the patient’s health record. The LumiraDx technology is designed to be cost-effective and applicable to many diagnostic assays, with a number of tests already in development and near to launch. The Platform will develop into a unique connected multi-test solution with the potential to accelerate diagnostic testing to improve clinical decision-making and patient experience, leading to better outcomes.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here